<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）在週三發佈的一份報告中，摩根大通的股票分析師將其目標價格從 93.00 美元上調至 101.00 美元，MarketScreener 報道。該券商目前對這家藥房運營商的股票給予 “增持” 評級。摩根大通的目標價格暗示該股票當前價格有 29.77% 的潛在上漲空間。</p>
<ul>
<li>CVS Health 因收入增長而上漲，股息保持強勁</li>
</ul>
<p>其他幾位股票分析師最近也對該股票發表了評論。Wolfe Research 將 CVS Health 的目標價格從 85.00 美元上調至 100.00 美元，並在 12 月 8 日的研究報告中給予該公司 “跑贏大盤” 評級。Barclays 將 CVS Health 的目標價格從 87.00 美元上調至 93.00 美元，並在 12 月 10 日的研究報告中給予該公司 “增持” 評級。高盛集團將 CVS Health 的目標價格從 93.00 美元上調至 95.00 美元，並在 12 月 10 日的研究報告中給予該股票 “買入” 評級。摩根士丹利將 CVS Health 的目標價格從 89.00 美元上調至 93.00 美元，並在 12 月 10 日的研究報告中給予該股票 “增持” 評級。最後，瑞銀集團在 12 月 10 日的報告中重申了對 CVS Health 的 “跑贏大盤” 評級。兩位股票研究分析師給予該股票 “強烈買入” 評級，二十位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat.com 的數據，CVS Health 目前的共識評級為 “適度買入”，共識目標價格為 94.67 美元。</p>
<p><strong>查看我們關於 CVS Health 的最新報告</strong></p>
<h2>CVS Health 價格表現</h2>
<ul>
<li>MarketBeat 週報 – 05/12 - 05/16</li>
</ul>
<p>CVS Health 的股票在週三開盤價為 77.83 美元。CVS Health 的 1 年低點為 43.56 美元，1 年高點為 85.15 美元。該公司的 50 日簡單移動平均線為 79.05 美元，200 日簡單移動平均線為 72.20 美元。該公司的流動比率為 0.83，速動比率為 0.63，債務與股本比率為 0.83。該股票的市值為 988 億美元，市盈率為 206.18，PEG 比率為 0.79，貝塔值為 0.48。</p>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）於 10 月 29 日發佈了最新的財報。這家藥房運營商報告本季度每股收益為 1.60 美元，超出分析師一致預期的 1.36 美元，超出幅度為 0.24 美元。CVS Health 的淨利潤率為 0.12%，股本回報率為 11.45%。該公司本季度的收入為 1028.7 億美元，而分析師預期為 988.5 億美元。去年同期，該公司的每股收益為 1.09 美元。該公司的收入同比增長 7.8%。CVS Health 已將其 2025 財年的指導目標設定為每股收益 6.550-6.650 美元。平均而言，賣方分析師預計 CVS Health 今年的每股收益為 5.89 美元。</p>
<h2>機構投資者對 CVS Health 的看法</h2>
<ul>
<li>現在是買入 Novo Nordisk 股票的好時機嗎？</li>
</ul>
<p>大型投資者最近買入和賣出了該公司的股票。SOA Wealth Advisors LLC 在第三季度將其在 CVS Health 的持股增加了 36.9%。SOA Wealth Advisors LLC 目前擁有 486 股該藥房運營商的股票，價值 37,000 美元，此前在該期間內又購買了 131 股。Alteri Wealth LLC 在第三季度將其在 CVS Health 的持股增加了 3.2%。Alteri Wealth LLC 目前擁有 4,195 股該藥房運營商的股票，價值 316,000 美元，此前在該期間內又購買了 131 股。Holistic Financial Partners 在第三季度將其在 CVS Health 的持股增加了 4.1%。Holistic Financial Partners 目前擁有 3,397 股該藥房運營商的股票，價值 256,000 美元，此前在上個季度又購買了 133 股。CYBER HORNET ETFs LLC 在第三季度將其在 CVS Health 的持股增加了 4.1%。CYBER HORNET ETFs LLC 目前擁有 3,442 股該藥房運營商的股票，價值 259,000 美元，此前在該期間內又購買了 134 股。最後，Fayez Sarofim &amp; Co 在第三季度將其在 CVS Health 的持股增加了 2.1%。Fayez Sarofim &amp; Co 目前擁有 6,913 股該藥房運營商的股票，價值 521,000 美元，此前在上個季度又購買了 140 股。80.66% 的股票目前由機構投資者持有。</p>
<h2>CVS Health 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房與消費者健康三個部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
<h2>另請參閲</h2>
<ul>
<li>五隻我們更看好的股票，勝過 CVS Health</li>
<li>市盈率計算：如何評估股票</li>
<li>三隻下跌超過 60% 的科技股——哪一隻值得購買？</li>
<li>成長股：它們是什麼，示例及如何投資</li>
<li>25 年後，思科終於從互聯網泡沫崩潰中恢復</li>
<li>三隻值得考慮的股息王</li>
<li>AI 芯片離不開這兩家被低估的科技巨頭</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>摩根大通已將 CVS Health 的目標股價從 93.00 美元上調至 101.00 美元，維持 “增持” 評級，暗示潛在上漲幅度為 29.77%。其他分析師，包括 Wolfe Research 和巴克萊，也提高了他們的目標股價，CVS Health 獲得了共識 “適度買入” 評級。該股開盤價為 77.83 美元，市值為 988 億美元。CVS Health 報告了強勁的收益，年同比收入增長 7.8%</p>

<p>CVS Health (NYSE:CVS - Get Free Report) had its target price lifted by stock analysts at JPMorgan Chase &amp; Co. from $93.00 to $101.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has an &#34;overweight&#34; rating on the pharmacy operator's stock. JPMorgan Chase &amp; Co.'s price target would suggest a potential upside of 29.77% from the stock's current price.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）在週三發佈的一份報告中，摩根大通的股票分析師將其目標價格從 93.00 美元上調至 101.00 美元，MarketScreener 報道。該券商目前對這家藥房運營商的股票給予 “增持” 評級。摩根大通的目標價格暗示該股票當前價格有 29.77% 的潛在上漲空間。</p>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 因收入增長而上漲，股息保持強勁</li>
</ul>
</div><p>Several other equities analysts have also recently commented on the stock. Wolfe Research upped their target price on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday, December 8th. Barclays increased their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. The Goldman Sachs Group increased their price target on shares of CVS Health from $93.00 to $95.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, December 10th. Morgan Stanley raised their price target on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Finally, UBS Group reissued an &#34;outperform&#34; rating on shares of CVS Health in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $94.67.</p>
<div class="lb-trans"><p>其他幾位股票分析師最近也對該股票發表了評論。Wolfe Research 將 CVS Health 的目標價格從 85.00 美元上調至 100.00 美元，並在 12 月 8 日的研究報告中給予該公司 “跑贏大盤” 評級。Barclays 將 CVS Health 的目標價格從 87.00 美元上調至 93.00 美元，並在 12 月 10 日的研究報告中給予該公司 “增持” 評級。高盛集團將 CVS Health 的目標價格從 93.00 美元上調至 95.00 美元，並在 12 月 10 日的研究報告中給予該股票 “買入” 評級。摩根士丹利將 CVS Health 的目標價格從 89.00 美元上調至 93.00 美元，並在 12 月 10 日的研究報告中給予該股票 “增持” 評級。最後，瑞銀集團在 12 月 10 日的報告中重申了對 CVS Health 的 “跑贏大盤” 評級。兩位股票研究分析師給予該股票 “強烈買入” 評級，二十位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat.com 的數據，CVS Health 目前的共識評級為 “適度買入”，共識目標價格為 94.67 美元。</p>
</div><p><strong>Check Out Our Latest Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVS Health 的最新報告</strong></p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 價格表現</h2>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 05/12 - 05/16</li>
</ul>
</div><p>Shares of CVS Health stock opened at $77.83 on Wednesday. CVS Health has a 1-year low of $43.56 and a 1-year high of $85.15. The firm has a fifty day simple moving average of $79.05 and a 200-day simple moving average of $72.20. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $98.80 billion, a price-to-earnings ratio of 206.18, a PEG ratio of 0.79 and a beta of 0.48.</p>
<div class="lb-trans"><p>CVS Health 的股票在週三開盤價為 77.83 美元。CVS Health 的 1 年低點為 43.56 美元，1 年高點為 85.15 美元。該公司的 50 日簡單移動平均線為 79.05 美元，200 日簡單移動平均線為 72.20 美元。該公司的流動比率為 0.83，速動比率為 0.63，債務與股本比率為 0.83。該股票的市值為 988 億美元，市盈率為 206.18，PEG 比率為 0.79，貝塔值為 0.48。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts' consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. During the same quarter in the previous year, the business earned $1.09 EPS. The business's revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, sell-side analysts expect that CVS Health will post 5.89 earnings per share for the current year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）於 10 月 29 日發佈了最新的財報。這家藥房運營商報告本季度每股收益為 1.60 美元，超出分析師一致預期的 1.36 美元，超出幅度為 0.24 美元。CVS Health 的淨利潤率為 0.12%，股本回報率為 11.45%。該公司本季度的收入為 1028.7 億美元，而分析師預期為 988.5 億美元。去年同期，該公司的每股收益為 1.09 美元。該公司的收入同比增長 7.8%。CVS Health 已將其 2025 財年的指導目標設定為每股收益 6.550-6.650 美元。平均而言，賣方分析師預計 CVS Health 今年的每股收益為 5.89 美元。</p>
</div><h2>Institutional Investors Weigh In On CVS Health</h2>
<div class="lb-trans"><h2>機構投資者對 CVS Health 的看法</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是買入 Novo Nordisk 股票的好時機嗎？</li>
</ul>
</div><p>Large investors have recently bought and sold shares of the business. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after buying an additional 131 shares during the period. Alteri Wealth LLC lifted its stake in shares of CVS Health by 3.2% in the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator's stock valued at $316,000 after purchasing an additional 131 shares during the period. Holistic Financial Partners boosted its position in shares of CVS Health by 4.1% during the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator's stock valued at $256,000 after purchasing an additional 133 shares in the last quarter. CYBER HORNET ETFs LLC grew its stake in CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator's stock worth $259,000 after purchasing an additional 134 shares during the period. Finally, Fayez Sarofim &amp; Co raised its holdings in CVS Health by 2.1% in the third quarter. Fayez Sarofim &amp; Co now owns 6,913 shares of the pharmacy operator's stock worth $521,000 after purchasing an additional 140 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近買入和賣出了該公司的股票。SOA Wealth Advisors LLC 在第三季度將其在 CVS Health 的持股增加了 36.9%。SOA Wealth Advisors LLC 目前擁有 486 股該藥房運營商的股票，價值 37,000 美元，此前在該期間內又購買了 131 股。Alteri Wealth LLC 在第三季度將其在 CVS Health 的持股增加了 3.2%。Alteri Wealth LLC 目前擁有 4,195 股該藥房運營商的股票，價值 316,000 美元，此前在該期間內又購買了 131 股。Holistic Financial Partners 在第三季度將其在 CVS Health 的持股增加了 4.1%。Holistic Financial Partners 目前擁有 3,397 股該藥房運營商的股票，價值 256,000 美元，此前在上個季度又購買了 133 股。CYBER HORNET ETFs LLC 在第三季度將其在 CVS Health 的持股增加了 4.1%。CYBER HORNET ETFs LLC 目前擁有 3,442 股該藥房運營商的股票，價值 259,000 美元，此前在該期間內又購買了 134 股。最後，Fayez Sarofim &amp; Co 在第三季度將其在 CVS Health 的持股增加了 2.1%。Fayez Sarofim &amp; Co 目前擁有 6,913 股該藥房運營商的股票，價值 521,000 美元，此前在上個季度又購買了 140 股。80.66% 的股票目前由機構投資者持有。</p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房與消費者健康三個部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li>
<li>3 Dividend Kings To Consider</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 CVS Health</li>
<li>市盈率計算：如何評估股票</li>
<li>三隻下跌超過 60% 的科技股——哪一隻值得購買？</li>
<li>成長股：它們是什麼，示例及如何投資</li>
<li>25 年後，思科終於從互聯網泡沫崩潰中恢復</li>
<li>三隻值得考慮的股息王</li>
<li>AI 芯片離不開這兩家被低估的科技巨頭</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

摩根大通對西維斯健康（NYSE:CVS）股票價格發佈了樂觀的預測